Xeris Pharmaceuticals Inc. (XERS) Tops Q2 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 10, 2020 7:00 AM EDTGvoke® net sales were $2.0 million in Q2 2020
Gvoke PFS prescriptions grew 72% quarter over quarter
July availability of Gvoke HypoPen accelerates prescription growth
June capital raise significantly strengthens balance sheet
Company to host a conference call and webcast today at 8:30 a.m. ET
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today... More
